Perfinity

Perfinity Biosciences Inc., founded in 2010 by Fred Regnier and Steve Plump, operates within the biotechnology sector, specializing in the development and manufacturing of products that automate protein sample preparation for mass spectrometry. The company, formerly known as QuadraSpec, Inc., is located in the Purdue Research Park of West Lafayette, Indiana. The foundation of the company is rooted in the extensive research of co-founder Fred Regnier, a Distinguished Professor of Chemistry at Purdue University and a renowned figure in proteomics and chromatography. His work has been instrumental in the development of life-saving biopharmaceuticals. Dr. Regnier has co-founded several other science companies, bringing a wealth of entrepreneurial and scientific experience to Perfinity.

The company's core business revolves around providing tools and reagents that significantly accelerate and simplify protein analysis for its clients, who are primarily pharmaceutical and biotech companies. Revenue is generated through the sale of consumable products and automated instrument solutions. A key offering is the Perfinity Digestion Platform (PDP), an automated system that dramatically reduces the time for trypsin digestion—a critical step in sample preparation for mass spectrometry—from roughly 18 hours to less than two minutes. This platform, which can be combined with liquid chromatography and mass spectrometry instruments from partners like Thermo Fisher Scientific, enables clients to monitor the purity of protein-based products in near real-time, preventing costly losses from protein oxidation.

Perfinity's product lineup includes various consumable columns, such as Trypsin and Lys-C columns, buffer and solution kits, and other reagents designed for its automated platforms. The company also developed the integrated Digestion Platform (iDP), which automates protein digestion, desalting, and reversed-phase chromatography to improve reproducibility and laboratory productivity. These products are crucial for applications in biopharmaceutical process monitoring, drug development, biomarker discovery, and protein purification. In June 2010, the company secured $2.33 million in a seed funding round from investors including Spring Mill Venture Partners and Purdue Foundry to support its growth.

Keywords: protein sample preparation, mass spectrometry, proteomics, biopharmaceuticals, automated protein digestion, trypsin digestion, chromatography, drug development, biomarker discovery, protein analysis, biotechnology, life sciences, Perfinity Digestion Platform, laboratory automation, protein purification, bioprocess monitoring, liquid chromatography, reagents, consumable kits, analytical instruments